New Horizon Health (“NHH”), a leading Chinese molecular diagnostic company focusing on early cancer detection, has closed its USD 30mn Series E round financing led by US-based Rock Springs Capital. New investors participated in this round of financing include OrbiMed, Lilly Asia Ventures, Cormorant Asset Management, CR-CP Life Science Fund, and Octagon Capital while existing backer Qiming Venture Partners also joined the financing. After its Series E round financing, total capital raised by the Company has reached over USD 160mn.

The proceeds for this financing will be used for its business development, new product R&D, clinical research and commercialization.

VMS led the Series C round financing and has participated in its Series D round financing.

Please refer to the link below for further details:
https://www.dealstreetasia.com/stories/china-deal-monitor-new-horizon-health-196720/